A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mia C Weiss
Yale University Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
- Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- Uf Health Cancer Institute - Gainesville
Gainesville, Florida, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
- Weisberg Cancer Treatment Center
Farmington Hills, Michigan, United States
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center
New York, New York, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- Vcu Massey Comprehensive Cancer Center
Richmond, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 19 Aug 2019
- Primary completion
- 1 Aug 2020
- Completion
- 12 Nov 2026
- Last update posted
- 2 Jun 2026
- Registered enrollment
- 23
- Registry id
- NCT03880019
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.